RXi PHARMACEUTICALS CORPORATION (NASDAQ:RXII) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

0

RXi PHARMACEUTICALS CORPORATION (NASDAQ:RXII) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item5.03. Amendments to Articles of Incorporation; Change in
Fiscal Year

In connection with an underwritten offering of common stock,
preferred stock and warrants, on December19, 2016, RXi
Pharmaceuticals Corporation (the Company) filed a Certificate of
Designation of Preferences, Rights and Limitations of Series B
Convertible Preferred Stock (the Series B Convertible Preferred
Stock Certificate of Designation) with the Secretary of State of
the State of Delaware. The Series B Convertible Preferred Stock
Certificate of Designation provides for the issuance of up to
8,100 shares of Series B Convertible Preferred Stock (the Series
B Convertible Preferred Shares).

The Series B Convertible Preferred Stock Certificate of
Designation provides, among other things, that holders of SeriesB
Convertible Preferred Stock shall receive dividends on an
as-converted basis at the same time and in the same form as any
dividends paid out on shares of our common stock. Other than as
set forth in the previous sentence, the Series B Convertible
Preferred Stock Certificate of Designation provides that no other
dividends shall be paid on Series B Convertible Preferred Stock.
The SeriesB Convertible Preferred Stock Certificate of
Designation does not provide for any restriction on the
repurchase of SeriesB Convertible Preferred Stock by the Company
while there is any arrearage in the payment of dividends on the
SeriesB Convertible Preferred Stock. There are no sinking fund
provisions applicable to the Series B Convertible Preferred
Stock.

With certain exceptions, as described in the Series B Convertible
Preferred Stock Certificate of Designation, the SeriesB
Convertible Preferred Stock have no voting rights. However, as
long as any shares of SeriesB Convertible Preferred Stock remain
outstanding, the Series B Convertible Preferred Stock Certificate
of Designation provides that the Company shall not, without the
affirmative vote of holders of a majority of the then-outstanding
Series B Convertible Preferred Stock, (a)alter or change
adversely the powers, preferences or rights given to the Series B
Convertible Preferred Stock or alter or amend the Series B
Convertible Preferred Stock Certificate of Designation,
(b)increase the number of authorized shares of Series B
Convertible Preferred Stock or (c)effect a stock split or reverse
stock split of the Series B Convertible Preferred Stock or any
like event.

Each Series B Convertible Preferred Share is convertible at any
time at the holders option into a number of shares of common
stock equal to $1,000 per share divided by the Series B
Convertible Preferred Share Conversion Price. The Series B
Convertible Preferred Share Conversion Price is initially $0.90
and is subject to adjustment for stock splits, stock dividends,
distributions, subdivisions and combinations. Notwithstanding the
foregoing, the Series B Convertible Preferred Stock Certificate
of Designation further provides that the Company shall not effect
any conversion of Series B Convertible Preferred Stock, with
certain exceptions, to the extent that, after giving effect to an
attempted conversion, the holder of Series B Convertible
Preferred Stock (together with such holders affiliates, and any
other person whose beneficial ownership of common stock would be
aggregated with the holders for purposes of Section 13(d) of the
Exchange Act and the applicable regulations thereunder, including
any group of which the holder is a member) would beneficially own
a number of shares of common stock in excess of 4.99% of the
shares of our common stock then outstanding.

This foregoing description of the Series B Convertible Preferred
Stock Certificate of Designation does not purport to be complete
and is qualified in its entirety by reference to the complete
text of such certificate, which is attached hereto and
incorporated herein.

Item5.07. Submission of Matters to a Vote of Security
Holders.

On December15, 2016, the Company held its 2016 Annual Meeting of
Stockholders (the Annual Meeting). The following items of
business were considered and voted upon at the Annual Meeting:
(i)election of five director nominees to serve until the 2017
annual meeting; (ii)ratification of the selection of BDO USA, LLP
as the Companys independent registered public accounting firm for
the fiscal year ending December31, 2016, (iii) an advisory
(non-binding) vote to approve the Companys executive
compensation, (iv)an increase in the number of shares available
for issuance under the RXi Pharmaceuticals Corporation Employee
Stock Purchase Plan and (v)an increase in the number of shares
available for issuance under the 2012 RXi Pharmaceuticals
Corporation Long Term Incentive Plan.

The number of shares of common stock entitled to vote at the
Annual Meeting was 6,599,846. The number of shares of common
stock present or represented by valid proxy at the annual meeting
was 4,425,173. All

2

matters submitted to a binding vote of stockholders at the Annual
Meeting were approved. The number of votes cast for and against,
and the number of abstentions and broker non-votes with respect to the
matters voted upon at the Annual Meeting, are set forth
below:

(i)Election of
Directors.

Director Nominee

VotesFor VotesWithheld

Geert Cauwenbergh, Dr.Med. Sc.

608,340 177,014

Robert J. Bitterman

681,123 104,231

Keith L. Brownlie

692,759 92,595

H. Paul Dorman

692,483 92,871

Curtis A. Lockshin, Ph.D.

692,573 92,781

There were
3,639,819 broker non-votes regarding the election of each
director.

(ii)Ratification
of Auditors.

Stockholders
ratified the appointment of BDO USA, LLP as the Companys
independent registered public accounting firm for the fiscal year
ending December31, 2016. The results of the voting were 4,214,232
votes for, 160,866 votes against and 50,075 abstentions. There
were no broker non-votes regarding this proposal.

(iii)Advisory
(non-binding) Vote with Respect to Executive
Compensation.

Stockholders
approved, on a non-binding advisory basis, the compensation paid
to the Companys named executive officers, as described in the
Companys definitive proxy statement for the Annual Meeting. The
results of the voting were 498,852 votes for, 234,205 votes
against and 52,297 abstentions. There were 3,639,819 broker
non-votes
regarding this proposal.

(iv)Increase in
the Number of Shares Available for Issuance under the RXi
Pharmaceuticals Corporation Employee Stock Purchase
Plan.

Stockholders approved an
increase in the number of shares available for issuance under the
RXi Pharmaceuticals Corporation Employee Stock Purchase Plan. The
results of the voting were 609,374 votes for, 154,753 votes
against and 21,227 abstentions. There were 3,639,819 broker
non-votes
regarding this proposal.

(v)Increase in the
Number of Shares Available for Issuance under the 2012 RXi
Pharmaceuticals Corporation Long Term Incentive
Plan.

Stockholders approved an
increase in the number of shares available for issuance under the
2012 RXi Pharmaceuticals Corporation Long Term Incentive Plan.
The results of the voting were 571,304 votes for, 192,598 votes
against and 21,452 abstentions. There were 3,639,819 broker
non-votes
regarding this proposal.

Item7.01. Regulation
FD Disclosure.

On December21, 2016, the
Company issued a press release in connection with the closing of
an underwritten offering of common stock, preferred stock and
warrants, RXi Pharmaceuticals Announces Closing of $11.5
Million Underwritten Public Offering and Full Exercise of
Over-allotment Option
. A copy of this press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated by reference into this Item
7.01

3

Item9.01. Financial
Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

3.1 Certificate of Designation of Preferences, Rights and
Limitations of Series B Convertible Preferred Stock, filed
with the Delaware Secretary of State on December19, 2016.
99.1 Press release of RXi Pharmaceuticals Corporation, dated
December21, 2016.

* *
*

4


About RXi PHARMACEUTICALS CORPORATION (NASDAQ:RXII)